The Proteoglycan Syndecan 4 Regulates Transient Receptor Potential Canonical 6 Channels via RhoA/Rho-associated Protein Kinase Signaling by Liu, Y. et al.
The Proteoglycan Syndecan 4 Regulates Transient Receptor
Potential Canonical 6 Channels via RhoA/Rho-associated
Protein Kinase Signaling
Ying Liu, Frank Echtermeyer, Florian Thilo, Gregor Theilmeier, Antje Schmidt, Ralf
Schülein, Boye L. Jensen, Christoph Loddenkemper, Vera Jankowski, Niels Marcussen,
Maik Gollasch, William J. Arendshorst, and Martin Tepel
Odense University Hospital, Department of Nephrology, and University of Southern Denmark,
Institute for Molecular Medicine, Cardiovascular and Renal Research, Institute of Clinical
Research, Odense, Denmark (Y.L., B.L.J., M.T.); Department of Medicine, Division of
Nephrology, Charité Campus Benjamin Franklin, Berlin, Germany (Y.L., F.T., V.J., M.T.);
Department of Urology, Tenth People’s Hospital, Tongji University of Shanghai, People’s
Republic of China (Y.L.); Department of Anesthesiology and Intensive Care Medicine, Medical
University Hannover, Hannover, Germany (F.E., G.T.); Max-Delbrück-Center of Molecular
Medicine, Berlin, Germany (A.S.); Leibniz-Institute for Molecular Pharmacology, Berlin, Germany
(R.S.); Institute of Pathology, Technical University Munich, Munich, Germany (C.L.); Institute of
Pathology, Charité Campus Benjamin Franklin, Berlin, Germany (C.L.); Department of Clinical
Pathology, Odense University Hospital, Odense, Denmark (N.M.); Medical Clinic for Nephrology
and Intensive Care Medicine, Charité Campus Virchow, Berlin, Germany (M.G.); Experimental
and Clinical Research Center, Berlin, Germany (M.G.); Cell and Molecular Physiology, University
of North Carolina at Chapel Hill, Chapel Hill, NC (W.J.A.)
Abstract
Objective—Syndecan 4 (Sdc4) modulates signal transduction and regulates activity of protein
channels. Sdc4 is essential for the regulation of cellular permeability. We hypothesized that Sdc4
may regulate transient receptor potential canonical 6 (TRPC6) channels, a determinant of
glomerular permeability, in a RhoA/Rho-associated protein kinase-dependent manner.
Methods and Results—Sdc4 knockout (Sdc4−/−) mice showed increased glomerular filtration
rate and ameliorated albuminuria under baseline conditions and after bovine serum albumin
overload (each P<0.05). Using reverse transcription–polymerase chain reaction and
immunoblotting, Sdc4−/− mice showed reduced TRPC6 mRNA by 79% and TRPC6 protein by
82% (each P<0.05). Sdc4−/− mice showed an increased RhoA activity by 87% and increased
phosphorylation of ezrin in glomeruli by 48% (each P<0.05). Sdc4 knockdown in cultured
podocytes reduced TRPC6 gene expression and reduced the association of TRPC6 with plasma
membrane and TRPC6-mediated calcium influx and currents. Sdc4 knockdown inactivated
negative regulatory protein Rho GTPase activating protein by 33%, accompanied by a 41%
increase in RhoA activity and increased phosphorylation of ezrin (P<0.05). Conversely,
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overexpression of Sdc4 reduced RhoA activity and increased TRPC6 protein and TRPC6-
mediated calcium influx and currents.
Conclusion—Our results establish a previously unknown function of Sdc4 for regulation of
TRPC6 channels and support the role of Sdc4 for the regulation of glomerular permeability.
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Syndecan 4 (Sdc4), a member of the type I transmembrane heparan sulfate proteoglycan
superfamily, is a major modulator of signal transduction and regulates localization and
activity of proteins and channels.1–3 Sdc4 consists of an extracellular N-terminal domain
with several heparan sulfate side chains, a single hydrophobic transmembrane domain, and a
short C-terminal cytoplasmic domain. Several unique Sdc4 functions have been described,
including binding of growth factors, modulation of the RhoA activity, modulation of the
activity of ezrin (which cross-links the plasma membrane with actin cytoskeleton), and
finally actin cytoskeleton organization.1–3 Recent reports implicate changes in Sdc4 with
kidney diseases.4–6 Sdc4 is upregulated 26 times in mice with proteinuric kidney disease.
Sdc4 transcript and protein levels are greatly elevated in glomerular disease.4 – 6 The
question arises whether Sdc4 regulates major functions in podocytes, which form a crucial
component of the glomerular filtration barrier. Podocytes are specialized cells in kidney
glomerulus that cover the urinary surface of the filtering capillaries, normally preventing
protein leakage into the urinary space.7 Recently, transient receptor potential canonical 6
(TRPC6) channels in podocytes have been recognized to regulate the glomerular filtration
barrier and serve as an important determinant of glomerular permeability.8 –12 Patients and
mice with proteinuric kidney disease show an increased expression of native TRPC6 in
podocytes.11,12 Thus, we reasoned that Sdc4 may regulate TRPC6 in podocytes and that this
mechanism could be the underlying cause of prevalent proteinuric kidney diseases related to
disturbed TRPC6 expression. In the present study, we show that Sdc4 regulates glomerular
permeability in mice and major functions in podocytes by affecting RhoA/Rho-associated
protein kinase activity and TRPC6 gene expression and function.
Materials and Methods
An extended Material and Methods section can be found in the supplemental material,
available online at http://atvb.ahajournals.org.
Conditionally immortalized mouse podocytes (podocyte cell line E11), human endothelial
cell line EA.hy926, human umbilical vein endothelial cells, and human embryonic kidney
cells (HEK293) were cultured as described.13,14 Small interfering RNA (siRNA)
knockdown of Sdc4 or TRPC6, isolation of RNA and cDNA synthesis, quantitative real-
time reverse transcription–polymerase chain reaction, overexpression of Sdc4 in podocytes,
immunoblotting of proteins and coimmunoprecipitation, quantitative in-cell Western assays
of proteins, immunofluorescence, isolation of glomeruli, and electron microscopy were
performed using standard techniques.14 –17 The visualization of green fluorescent protein
(GFP)–or yellow fluorescent protein (YFP)-tagged-TRPC6 in transfected cells, intra-cellular
calcium measurements, and matrix-assisted laser desorption/ ionization time-of-flight mass
spectrometry of isolated proteins have been described previously.18 –22 Rho GTPase
activating protein (RhoGAP), RhoA activity, podocyte membrane protein biotinylation and
isolation, patch clamp measurements, and permeability assay were performed as
described.23–25 Creation of Sdc4−/− mice has been reported previously,26 and the Animal
Use Committee for the Hannover Medical School (Niedersaechsisches Landesamt für
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Verbraucherschutz und Lebensmittelsicherheit, approval number 33.9-42502-04-08/1517)
approved all procedures.
Statistical Analysis
Data are expressed as the mean±SEM. Comparisons between groups were analyzed using t
test or ANOVA and Bonferroni multiple comparison test as appropriate. A 2-tailed
probability value less than 0.05 was considered to indicate statistical significance.
Results
Sdc4−/− Mice Show Reduced TRPC6 Transcripts, Proteins, and Urinary Albumin Excretion
In the present study, we compared TRPC6 expression in glomeruli of Sdc4−/− mice26 and
wild-type (Sdc4+/+) littermates. Our immunofluorescent results showed the expression of
TRPC6 protein in glomerular podocytes, as evidenced by colocalization with podocyte-
specific nephrin. TRPC6 protein expression (green) was reduced in Sdc4−/− compared with
Sdc4+/+ mice (Supplemental Figure IA). Immunoblotting confirmed a significant reduction
of TRPC6 protein by 82% in renal cortex of Sdc4−/− vs Sdc4+/+ mice. Notably, the protein
expression of TRPC3, podocin, and nephrin did not differ between groups (Figure 1A and
1B). We also observed a significant 79% (P<0.05) reduction in TRPC6 mRNA, whereas the
TRPC3 transcript was unchanged in Sdc4−/− mice (Figure 1C), providing further evidence
for selective regulation of TRPC6 by Sdc4. Most importantly, under baseline conditions
Sdc4−/− mice displayed reduced urinary albumin excretion (6.7±0.9 vs 3.9±0.4 g albumin/
mol creatinine; P<0.05; Figure 1D). Furthermore, an increased albuminuria after bovine
serum albumin overload was ameliorated in Sdc4−/− mice. Bovine serum albumin overload
enhanced urinary albumin excretion 2.5±0.4-fold in Sdc4−/− mice, whereas it enhanced
urinary albumin excretion 13.4±5.2-fold in Sdc4+/+ littermates (P<0.05; Figure 1E). Sdc4−/−
showed increased glomerular filtration rate, indicating healthy kidney function. Glomerular
filtration rate was higher in Sdc4−/− compared with Sdc4+/+ littermates (164±12 μL/min vs
101±2 μL/min; n=5 each, P<0.05). As expected, Sdc4 mRNA was absent in the renal cortex
of Sdc4−/− mice whereas Sdc3, Sdc2, and Sdc1 transcripts were not different between the 2
groups (Supplemental Figure IB). The kidney weight to body weight was 6.4±0.3 mg/g in
Sdc4−/− mice and 6.6±0.5 mg/g in wild-type littermates, respectively (n=5 each; P>0.05).
The ultrastructure of glomerular filtration barrier, including the foot process, slit diaphragm,
basement membrane, and endothelium, were structurally normal in Sdc4−/− mice, as
examined by electron microscopy (Supplemental Figure IC and ID). Collectively, our results
link parallel reductions in Sdc4 and TRPC6 with reduced urinary protein excretion. These
results are in line with findings showing the association of TRPC6 with proteinuria in
kidney diseases.8 –12
Sdc4−/− Mice Show Increased RhoA/ROCK Activity in Kidney Cortex
Sdc4 reportedly reduces RhoA activity via activation of p190RhoGAP-A, which is a
negative regulator of active Rho GTPase activity.27,28 Consistent with these findings,
Sdc4−/− mice showed an increase, 87% on the average (P<0.05), of RhoA activity in the
renal cortex (Figure 1F). RhoA is known to activate the cytoskeleton-related protein ezrin by
phosphorylation.29 In this regard, immunoblottings derived from freshly isolated glomeruli
showed that phosphorylated ezrin was significantly increased by 48% in Sdc4−/− mice
compared with Sdc4+/+ littermates (Figure 1G). Taken together, Sdc4−/− mice were
characterized by selectively reduced TRPC6 expression, reduced albuminuria, and increased
RhoA/ROCK activity. Eckel et al recently reported that reduced TRPC6 ameliorates
proteinuria in mice.30 Our present results give much experimental evidence that Sdc4 affects
RhoA/ROCK signaling, which controls TRPC6 expression. This was further confirmed by
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our in vitro experiments using Sdc4 knockdown and overexpression in glomerular
podocytes.
Sdc4 Knockdown Selectively Reduces, Whereas Sdc4 Overexpression Increases TRPC6
Transcripts and Proteins Levels in Podocytes
In the podocyte cell line E11, we identified transcripts for TRPC6 and Sdc4 (Supplemental
Figure IIA), the expression of TRPC6 and Sdc4 proteins, and the expression of podocyte-
specific proteins, including nephrin, podocin, WT1, and synaptopodin. Podocyte-specific
proteins were absent in 2 separate endothelial cell types, which were used as controls
(Supplemental Figure IIB). Hence, we and others confirmed their unique cellular properties
which characterize podocyte phenotype.13,20 Mass spectrometry verified that the detected
proteins were TRPC6 (Mascot score 183) and Sdc4 (Mascot score 84; Supplemental Figure
IIC). Administration of siRNA against Sdc4 reduced Sdc4 mRNA abundance by 51%
(P<0.05) but did not affect Sdc3, Sdc2, or Sdc1 mRNA expression (Figure 2A). Knockdown
of Sdc4 in vitro reduced TRPC6 mRNA by 25% (P<0.05), whereas TRPC3 was not affected
(Figure 2B). In agreement with our results obtained in Sdc4−/− mice, knockdown of Sdc4 in
cultured podocytes selectively reduced TRPC6 protein expression by 30% (P<0.05) but did
not affect TRPC3 protein, as assessed by immunoblotting (Figure 2C), immunofluorescence
(Supplemental Figure IID), quantitative fluorescence assays of green fluorescent protein-
tagged TRPC6 (green fluorescent protein [GFP]-tagged TRPC6) (Figure 2D), and a
quantitative in-cell Western assay (Supplemental Figure III). Control scrambled siRNA
showed no effects on TRPC6 protein expression (101±2% of control). We observed a
selectively increased TRPC6 protein expression in podocytes after transfection with Sdc4
full-length construct (Sdc4FL) but not with transfection with an Sdc4 construct lacking the
cytoplasmic domain (Sdc4CY) (Supplemental Figure III). TRPC6 protein expression was
enhanced by 40% (P<0.01) after Sdc4FL, whereas TRPC3 protein was not affected. Sdc4
protein was increased by 56% (P<0.01) in podocytes after Sdc4FL expression. Thus, our
results demonstrate that Sdc4 is a specific regulator of TRPC6, but not the other family
member TRPC3, in podocytes.
Sdc4 Knockdown Reduces, Whereas Sdc4 Overexpression Increases, TRPC6-Mediated
Cation Influx and Currents in Podocytes
TRPC6-mediated calcium influx into fluo-4-loaded podocytes was measured using confocal
laser scanning microscopy. Calcium influx was induced by the known TRPC6 agonist
flufenamic acid (FFA).31,32 siRNA against Sdc4 reduced the FFA-induced peak calcium
influx by 58% (P<0.01). In addition, increased TRPC6 channel density after transfection
with Sdc4FL enhanced calcium influx by 111% (P<0.01; Figure 3A). 1-Oleoyl-2-acetyl-sn-
glycerol, a diacylglycerol analog, triggered calcium influx was reduced by 49% (P<0.05)
after Sdc4 knockdown. This reduction by siRNA was prevented when calcium influx was
inhibited by the nonspecific TRPC blockers 2-aminoethoxydiphenylborane or SKF-96365,
providing further evidence for the involvement of TRPC6 channels. As shown in Figure 3B
to 3E, application of FFA caused increased cation currents showing a characteristic doubly
rectifying the current-voltage relationship of TRPC6 channels in podocytes.33 Moreover,
they could be blocked by 1 mmol/L gadolinium. Normalization of currents is shown in
Figure 3E. siRNA against Sdc4 reduced the FFA-induced cation currents at 100 mV by 59%
(P<0.01). In contrast, increased TRPC6 channel density after transfection with Sdc4FL
enhanced cation currents by 47% (P<0.05). Figure 3F shows that 1-oleoyl-2-acetyl-sn-
glycerol, a diacylglycerol analog, can trigger the TRPC-mediated currents in podocytes.
These data indicate that Sdc4 knockdown reduces, whereas Sdc4 overexpression increases,
TRPC6 channels and cation flux in podocytes.
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Sdc4 Regulates RhoA/ROCK Activity in Podocytes
Next, we investigated the possibility of direct interactions between endogenous TRPC6 or
GFP-tagged TRPC6 channel proteins and slit diaphragm proteins. In accordance with
previous reports, in cultured podocytes, we observed coimmunoprecipitation of TRPC6, as
well as GFP-tagged TRPC6, with the slit diaphragm protein nephrin.33 On the other hand,
coimmunoprecipitation revealed that Sdc4 is not a glomerular slit diaphragm-associated
protein (Figure 4A and 4B) but is associated with the cytoskeleton protein ezrin (Figure 4C).
Previous studies showed that Sdc4 regulates RhoA activity via RhoGAP, which is a negative
regulator of active RhoA.27 In accordance with these observations, knockdown of Sdc4
using siRNA against Sdc4 decreased the RhoGAP activity by 33% (P<0.05), accompanied
by a 41% (P<0.01) increase in RhoA activity. In contrast, overexpression of Sdc4 using
Sdc4FL, but not Sdc4CY, increased the RhoGAP activity by 30% (P<0.05), accompanied
by a 47% (P<0.01) reduction in RhoA activity (Figure 4D and 4E). The effects of Sdc4 on
RhoA activity after Sdc4 stimulation by fibronectin are summarized in Figure 4F. As shown
in Figure 4G, administration of fibronectin reduced phosphorylation of ezrin by 50%
(P<0.01). siRNA against Sdc4 abolished the inhibitory effect of fibronectin. In contrast,
overexpression of Sdc4 using Sdc4FL, but not Sdc4CY, augmented the inhibitory effects of
fibronectin on ezrin phosphorylation (P<0.01).
Sdc4 Facilitates the Insertion of TRPC6 Channels Into the Plasma Membrane of Podocytes
via the RhoA Pathway
Using GFP-tagged TRPC6 and confocal laser scanning microscopy, we observed that
TRPC6 is localized mainly to the plasma membrane of cultured podocytes (Supplemental
Figure IVA and IVB). Knockdown of Sdc4 reduced TRPC6 protein found in the plasma
membrane, whereas Sdc4FL, but not Sdc4CY, significantly increased the density of TRPC6
protein present in the plasma membrane (Figure 5A). As indicated above, in mice, Sdc4
modulated RhoA activity. Sdc4−/− mice showed increased RhoA activity and reduced
TRPC6. Next, we established that Rho kinase agonist calpeptin reduced TRPC6 protein
localized in the plasma membrane, thereby mimicking Sdc4 knockout. By contrast, 2
structurally independent Rho-kinase inhibitors, Y27632 and fasudil, significantly increased
TRPC6 protein targeting to the plasma membrane of podocytes, mimicking Sdc4 over-
expression (Figure 5B). These findings were supported by biotinylation assays (Figure 5C).
Immunoblotting demonstrated that the Rho kinase agonist calpeptin reduced plasma
membrane-associated TRPC6 protein by 55% (P<0.05), whereas the Rho-kinase inhibitor
Y27632 increased plasma membrane-associated TRPC6 protein by 78% (P<0.05).
Moreover, transient transfection of podocytes with YFP-tagged TRPC6 plasmid DNA
significantly increased podocyte monolayer permeability by 47% compared with controls
(transfected podocytes, 2.5±0.1; controls, 1.7±0.0; n=3 each; P<0.05; Figure 5D). Identical
results showing that Sdc4 enhances density of TRPC6 channels in the plasma membrane by
a RhoA-dependent pathway were obtained in HEK cells transfected with YFP-tagged
TRPC6 protein (Supplemental Figure IVC and IVD). In support of these results, insertion of
other ion channels by the RhoA pathway has been reported previously.34
Discussion
We identified a major role of Sdc4 in glomeruli. In particular, we observed that Sdc4
regulates glomerular permeability and podocytes’ functions by affecting RhoA/ROCK
activity and TRPC6 gene expression. Recent studies implicate that Sdc4 could participate in
kidney diseases.4 – 6 Furthermore, increased expression of TRPC6 in the podocyte slit
diaphragm and gain-of-function mutations in TRPC6 have been identified to cause podocyte
injury and human kidney disease.8,10,11 It still remains unknown whether Sdc4 is
responsible for the regulation of glomerular filtration. Now, we provide experimental
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evidence that Sdc4 regulates glomerular permeability by affecting TRPC6 expression in
podocytes. We found that (1) Sdc4−/− mice showed reduced TRPC6 mRNA, TRPC6
channel protein, and albuminuria, both under baseline conditions and after bovine serum
albumin overload, and increased RhoA/ROCK activity in kidney cortex compared with
wild-type littermates; (2) Sdc4 knockdown in podocytes decreased TRPC6 transcripts,
protein abundance, and TRPC6-mediated cation influx; and (3) Sdc4 knockdown increased
baseline podocyte RhoA activity and phosphorylation of the cytoskeleton-related protein
ezrin, thereby reducing the association of TRPC6 channel proteins with plasma membrane.
By contrast, overexpression of functionally intact Sdc4 reversed these effects.
Experiments on TRPC6−/− mice revealed that lack of TRPC6 expression cannot be
functionally replaced by TRPC3 in vivo.35 Our results demonstrate a specific Sdc4-TRPC6
interaction, which underscores TRPC subtype-specific characteristics of TRPC6 compared
with TRPC3. First, TRPC6 channels carry 2 extracellular N-linked glycosylation sites,
whereas TRPC3 channel is a monoglycosylated protein.36 Second, TRPC6 and TRPC3
show different electrophysiological characteristics. TRPC6 is a tightly receptor-regulated
store-independent cation channel, whereas TRPC3 displays considerable basal activity.37
Third, FFA seems to be a specific activator of TRPC6 but not other TRPC channel
proteins.31,32 In line with this, we found an increased FFA-induced calcium influx after
overexpression of Sdc4FL and consecutively increased TRPC6 channel protein expression.
Similarly, inward currents showing characteristic TRPC6 features24,32 were increased after
overexpression of Sdc4 using the Sdc4FL construct, but not after overexpression using the
Sdc4CY construct. This corroborates that Sdc4 is a specific regulator in podocytes
mediating plasma membrane association of TRPC6.
The features of Sdc4−/− mice have been reported previously. Ishiguro et al38 reported similar
blood pressure in conscious Sdc4−/− mice and wild-type littermates, and Partovian et al2
showed slightly increased blood pressure in anesthetized animals. Notably, the finding of
increased glomerular filtration rate in Sdc4−/− mice should be interpreted together with our
observation that Sdc4−/− mice showed reduced albuminuria and reduced TRPC6 expression
in podocytes. These findings are important for several human kidney diseases where reduced
glomerular filtration rate, increased proteinuria and increased TRPC6 expression have been
reported.11 Indeed, overexpression of functional TRPC6 is sufficient to cause increased
permeability in vitro.
To evaluate the role of Sdc4 for regulation of the TRPC6 gene expression, we studied Sdc4
and TRPC6 in cultured podocytes. Using reverse transcription–polymerase chain reaction
and immunoblotting, we identified their unique characteristics, which are indistinguishable
from those of native podocytes.13,20,39 We found that siRNA against Sdc4 reduced Sdc4
mRNA abundance by 51% and TRPC6 by 25% but did not affect Sdc3, Sdc2, Sdc1, TRPC3,
nephrin, or podocin mRNA expression. These data rule out the involvement of nonspecific
silencing during knockdown of Sdc4 using siRNA. Instead, these results strongly suggest
that Sdc4 or Sdc4-dependent signaling affects TRPC6 gene transcription. We used 4
different techniques to further characterize Sdc4-TRPC6 interactions, including
immunoblotting, quantitative fluorescence assay of fluorescent tagged TRPC channels,
immunofluorescence, and quantitative in-cell Western assay. Together, the results clearly
show that Sdc4 selectively affects TRPC6 channel protein expression and membrane
association in podocytes.
We further uncovered a mechanistic link between Sdc4 and TRPC6. Small GTPases have
been reported to act downstream of syndecans regulating several cellular functions.40,41 In
the present study, we found that overexpression of Sdc4FL reduced baseline RhoA activity
in podocytes. We also observed that overexpression of Sdc4FL inhibited RhoA/ROCK
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activity, as confirmed by reduced phosphorylation of ezrin. Ezrin, which binds to the
syndecan cytoplasmic domain, is known to link RhoA/ROCK activity with actin
cytoskeleton rearrangements.29 To the best of our knowledge the effects of Sdc4 on RhoA
activity have not been reported in podocytes. However in fibroblasts, Sdc4 showed variable
effects dependent on cell culture conditions, cooperative interactions between integrins and
syndecans with the extracellular matrix, and exposure time to different Sdc4-binding
substrates, including fibronectin. In accordance with our data in podocytes, Bass et al
showed that Sdc4 reduces RhoA activity in fibroblasts via activation of p190RhoGAP-A,
which is a negative regulator of active Rho GTPase.27 However, in rat embryo fibroblasts,
other groups reported conflicting results, showing that fibronectin may activate RhoA in a
Sdc4-dependent manner.42
Because the effects of Sdc4 on RhoA activity may be affected by culture conditions, it
should be noted that in the present study podocytes were seeded on plates without precoated
fibronectin, thereby avoiding premature Sdc4 activation. Moreover, exposure time may be
important. Hence, in the RhoA activity assay, podocytes were treated with fibronectin for
less than 30 minutes. In accordance with our findings, Ren et al showed that short-term
exposure inhibits RhoA activity in Swiss 3T3 cells.43
Rho-GTPases have a role in cytoskeletal rearrangement, but they also regulate vesicular
trafficking.40,41 Previous studies indicate that the RhoGAP, a negative regulator of RhoA,
promotes fusion of intracellular vesicles to the plasma membrane.44 TRPC6 channels are
localized in the plasma membrane and in caveolae-related microdomain vesicles subjacent
to the plasma membrane.45 Because Sdc4 affects RhoA/ROCK activity via RhoGAP, we
further investigated whether Sdc4/RhoGAP/RhoA/ROCK may affect TRPC6 channels in
cultured podocytes. Using confocal laser scanning microscopy and biotinylation assays, we
observed that the activation of RhoA/ROCK signaling, via inactivation of RhoGAP by Sdc4
knockdown or via treatment with RhoA/ ROCK activator, triggered the translocation of
TRPC6 channels from the plasma membrane into the cytoplasm. On the other hand, the
inhibition of RhoA/ROCK signaling, via activation of RhoGAP by overexpression of
functional Sdc4 or via treatment with RhoA/ROCK inhibitors, increased the plasma
membrane pool of TRPC6 channels. Our results established a previously unknown function
of Sdc4 for regulation of TRPC6 channels and supported a major role of Sdc4 for the
regulation of glomerular permeability. The wide tissue distribution of Sdc4 and TRPC6
channels in vasculature and our confirmation of these events in HEK293 cells strongly
suggest that the regulation of TRPC6 channels by proteoglycan Sdc4 via RhoA/ROCK
signaling may be a general process in vascular biology. The current studies suggest a direct
casual link between Sdc4 and TRPC6 in podocytes. However, we cannot rule out the
involvement of other glomerular components. A podocyte-specific knockout of Sdc4 may be
needed to confirm the current findings.
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Characteristics of wild-type (syndecan 4 [Sdc4]+/+) and Sdc4−/− mice. Both proteins (A and
B) (Western blotting, n=3; *P<0.05) and transcripts (C) (quantitative reverse transcription–
polymerase chain reaction, n=5; **P<0.01) of transient receptor potential canonical 6
(TRPC6) were reduced in glomeruli of Sdc4−/− mice. Sdc4−/− mice showed reduced urinary
albumin excretion under baseline conditions (D) (n=9–10; *P<0.05) and after bovine serum
albumin overload compared with Sdc4+/+ littermates (E) (n=4–5; *P<0.05). Sdc4−/− mice
showed increased RhoA activity (F) (n=5; *P<0.05) and phosphorylation of ezrin (pEzrin),
indicated by immunoblotting (G).
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Syndecan 4 (Sdc4) regulates transient receptor potential canonical 6 (TRPC6) expression in
podocytes. Podocytes transfected with small interfering RNA (siRNA) against Sdc4 showed
reduced transcripts for Sdc4 (A) and TRPC6 (B), but not Sdc3, Sdc2, Sdc1, or TRPC3
(quantitative reverse transcription–polymerase chain reaction; n=5– 8; **P<0.01).
Podocytes transfected with siRNA against Sdc4 showed reduced TRPC6 protein expression
(C) (n=4; *P<0.05). Sdc4 knockdown specifically reduced TRPC6 protein expression in
podocytes, as measured by quantitative fluorescence assays of green fluorescent protein
(GFP)–tagged TRPC6 (D) (n=4; **P<0.01).
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Syndecan 4 (Sdc4) regulates transient receptor potential canonical 6 (TRPC6)–mediated
calcium influx and membrane currents in podocytes. A, The cytosolic Ca2+ concentration in
response to 100 μmol/L flufenamic acid (FFA) was determined by Fluo-4. Pictures at
baseline, at peak calcium, and after recovery are shown, as well as summary data of peak
calcium influx. n=5; *P<0.05, **P<0.01. FFA-induced, TRPC6-mediated membrane
currents in podocytes (B), after Sdc4 knockdown (C), and Sdc4 overexpression (D) are
shown. siRNA indicates small interfering RNA. E, Normalization of currents (n=4). 1-
Oleoyl-2-acetyl-sn-glycerol (OAG), a diacylglycerol (DAG) analog, can trigger the TRPC-
mediated currents in podocytes (F).
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Syndecan 4 (Sdc4) is not attached to the slit membrane but interacts via RhoA pathway in
podocytes. Coimmunoprecipitation showing that endogenous transient receptor potential
canonical 6 (TRPC6) (A) and green fluorescent protein (GFP)–tagged TRPC6 (B) are
associated with slit diaphragm protein nephrin but not with Sdc4. C, Coimmunoprecipitation
showing that Sdc4 is associated with cytoskeleton protein ezrin. IP indicates primary
antibody used for immunoprecipitation; WB, primary antibody used for Western blotting;
eluate, immunoprecipitated proteins; lysate, total cell lysate control. n=3. RhoA activity is
shown in podocytes cultured under control conditions, after Sdc4 knockdown, or Sdc4
overexpression. Rho GTPase activating protein (RhoGAP) activity (D) and RhoA activity at
baseline (E) and after fibronectin (Fibro) administration (F) were compared between groups.
*P<0.05, **P<0.01 compared with control. ##P<0.01 compared with Fibro alone. G,
Phosphorylation of ezrin (pEzrin) in podocytes under control conditions, after Sdc4
knockdown or Sdc4 overexpression. Podocytes were stimulated with fibronectin. **P<0.01
compared with control.
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Syndecan 4 (Sdc4) enhances the density of transient receptor potential canonical 6 (TRPC6)
channels in the plasma membrane of podocytes via RhoA-dependent pathway. A,
Immunofluorescence showing that Sdc4 knockdown reduced, whereas Sdc4 overexpression
increased, TRPC6 protein localized in the plasma membrane of podocytes. Sdc4FL indicates
Sdc4 full-length construct; Sdc4CY, Sdc4 construct lacking cytoplasmic domain. Nephrin is
shown for comparison. Scale bar=5 μm. B, Rho kinase agonist calpeptin reduced TRPC6
protein localized in the plasma membrane, whereas Rho-kinase inhibitors, Y27632, and
fasudil increased it. C, Biotinylation assay demonstrating that activation of Rho kinase by
calpeptin reduced, whereas inhibition by Y27632 increased, plasma membrane-associated
TRPC6 protein (n=5; **P<0.01). Transient transfection of podocytes with YFP-tagged
TRPC6 plasmid DNA increased podocyte monolayer permeability (D) (n=3 each; P<0.05).
Liu et al. Page 15
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2014 January 06.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
